Prostate-specific membrane antigen (PSMA) has become the most important biomarker for prostate cancer diagnosis and therapy, as PSMA has been found to be overexpressed in 95% of PCa tumors, with increasing expression levels in higher-grade and metastatic lesions [1]. The gene discussed is FOLH1; the disease is Familial prostate cancer.